Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Evotec SENASDAQ: EVO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of €123.94M (cash outflow) rose 292.5% year over year, ahead of the -8.5% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -17.3% a year.

Context

  • Net income amounted to 13.1% of revenue in FY2025, down 11.5 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -€254.23M (+155.7%) for the fiscal year ending Dec 2026, a step up from the -49.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-€123.94M-955.5% QoQ
Last fiscal yearDec 2025
-€99.43M-49.3% YoY
LTMMar 2026
-€196.02M-8.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+292.5%-71.4%-363.9 pp
1 year-49.3%+155.7%+205.0 pp
3-year CAGR-17.3%-76.3%-59.0 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the cash flow

Latest · FY2025
(99.43M) EUR
Year-over-year change
+49.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.5% is the 8th highest of 11, against a peer median of +23.0%.
  • Net income amounts to 26.3% of revenue for EVO, versus a peer median of 16.3%.
EVO Competitors
Net Income for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TLRYTilray Brands, Inc.LTM Feb 2026$1.83B USD+35.0%+70.9%154.9%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$263.86M USD+77.1%+22.8%291.6%
EVOEvotec SELTM Mar 2026€196.02M EUR-8.5%-17.3%26.3%
PHVSPharvaris N.V.LTM Sep 2026€179.96M EUR+11.0%+31.9%—
NVCRNovoCure LimitedLTM Mar 2026$173.05M USD+5.4%+13.8%25.7%
TDOCTeladoc Health, Inc.LTM Mar 2026$171.15M USD-83.1%-75.5%6.8%
AZTAAzenta, Inc.LTM Sep 2026$166.99M USD+199.5%+125.1%26.9%
ALVOAlvotechLTM Mar 2026$80.73M USD-183.6%—14.4%
SDGRSchrödinger, Inc.LTM Sep 2026$44.01M USD+125.0%-11.5%16.3%
HROWHarrow Health, Inc.LTM Mar 2026$14.96M USD-31.0%-28.5%5.6%
PCRXPacira BioSciences, Inc.LTM Mar 2026$5.14M USD+105.0%-23.8%0.7%
Peer median (excluding EVO) —+23.0%+13.8%16.3%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Depreciation & Amortization67.61M83.2M92.98M101.62M95.55M
Deferred Income Tax5.07M21.7M3.32M2.1M14.11M
Stock-Based Compensation7.81M9.92M9.63M5.04M0
Change in Working Capital(2.28M)105.29M(9.94M)(68.21M)(58.4M)
Accounts Receivables(48.03M)(53.68M)00(27.6M)
Inventory(11.65M)(4.41M)00(9.18M)
Accounts Payables31.34M24.55M00(7.02M)
Other Working Capital26.06M138.83M(9.94M)(68.21M)(14.61M)
Other Non-Cash Items(171.47M)161.37M24.37M173.75M39.11M
Operating Cash Flow122.24M205.81M36.44M18.22M(9.06M)
Capital Expenditures(118.94M)(181.35M)(216M)(132.24M)(69.68M)
Acquisitions (Net)(21.09M)(83.82M)(20.16M)42.78M213.76M
Purchases of Investments(123.7M)(355.82M)(48.39M)(29.39M)(13.42M)
Sales of Investments27.25M205.17M260.36M35.67M38.87M
Other Investing Activities(7.38M)3.03M8.22M(2.78M)0
Investing Cash Flow(243.86M)(412.8M)(13.29M)(71.19M)159.86M
Debt Repayment14.77M(53.11M)84.6M(152.07M)(6.96M)
Common Stock Issued404.32M355K00(1.27M)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(20.67M)(5.39M)(12.63M)(9.35M)(22.71M)
Financing Cash Flow398.43M(58.15M)71.96M(161.42M)(30.93M)
Effect of Forex Changes(66K)(19.04M)644K9.87M28.46M
Net Change in Cash276.75M(284.17M)95.75M(204.52M)148.32M
Free Cash Flow3.29M24.46M(179.56M)(114.02M)(78.74M)

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.